Longeveron (LGVN) Debt Ratio (2021 - 2023)

Longeveron (LGVN) posted quarterly Debt Ratio of 0.05 for Q3 2023, up 49.07% quarter-over-quarter from 0.03 in Q2 2023.

Longeveron (LGVN) Debt Ratio (2021 - 2023) Analysis & Trends

Longeveron's Debt Ratio history runs 3 years deep, the most recent figure standing at 0.05 for Q3 2023.

In Q3 2023, Debt Ratio changed N/A year-over-year to 0.05; the TTM figure through Sep 2023 stood at 0.05 (changed N/A YoY), while the FY2022 annual figure was 0.02, up 63.85% from the prior year.
Debt Ratio for Q3 2023 stood at 0.05, up from 0.03 in the prior quarter.
The five-year high for Debt Ratio was 0.05 in Q3 2023, with the low at 0.01 in Q4 2021.
The 3-year median for Debt Ratio is 0.03 (2023), against an average of 0.03.
Peak annual rise in Debt Ratio reached 63.85% in 2022, while the deepest fall reached 63.85% in 2022.
Longeveron's Debt Ratio stood at 0.01 in 2021, then surged by 63.85% to 0.02 in 2022, then soared by 145.01% to 0.05 in 2023.
Business Quant data shows LGVN's Debt Ratio at 0.05 in Q3 2023, 0.03 in Q2 2023, and 0.03 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Longeveron	26.51 Mn	16.41 Mn	182,000.00	-

Download Data